Drug
E7777 KG
E7777 KG: highest development phase Phase 3, developed by Eisai. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Eisai
Trials
| Drug | Phase | Indication |
|---|---|---|
| E7777 9 mcg/kg NCT01871727 | Phase 3 | Persistent or Recurrent Cutaneous T-Cell Lymphoma |
Latest
No recent events.
Follow E7777 KG on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.